Comparative Study on Empirical Medication and Medication under the Guidance of ATP-TCA in the Treat-ment of Platinum Resistant Recurrent Ovarian Cancer
10.6039/j.issn.1001-0408.2016.17.30
- VernacularTitle:铂耐药复发卵巢癌经验用药与三磷酸腺苷-肿瘤体外药敏试验指导下用药的对比研究
- Author:
Jianxin WANG
- Publication Type:Journal Article
- Keywords:
Platinum resistance recurrent ovarian cancer;
Empirical medication;
Adenosine triphosphate-tumor chemosensitivity assay;
Chemotherapy efficacy;
Survival rate
- From:
China Pharmacy
2016;27(17):2394-2396,2397
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To compared with empirical medication and medication under the guidance of adenosine triphos-phate-tumor chemosensitivity assay (ATP-TCA) in the treatment of platinum resistance recurrent ovarian cancer,and to explore clinical efficacy,survival situation of the occurrence of ADR. METHODS:90 cases of platinum resistant recurrent ovarian cancer were divided into drug sensitive group(46 cases)and control group(44 cases)according to admission order. According to clinical experience,control group was given gemcitabine+ifosfamide+doxorubicin for chemotherapy;according to the ATP-TCA test re-sults,chemotherapy plan of drug sensitive group was determined. A treatment course of 2 groups lasted for 28 d,and both received 2-6 courses of chemotherapy. Chemotherapy efficacy,survival situation and the occurrence of ADR were compared between 2 groups. RESULTS:18 cases receiving paclitaxel,14 cases receiving doxorubicin,6 cases paclitaxe+vinorelbine,5 cases gemcitabi-ne,3 cases topotecan in the drug sensitive group. The total effective rate of drug sensitive group was 58.70%,which was signifi-cantly higher than that(36.96%)of control group,with statistical significance(P<0.05). The progression free survival and medi-an survival of drug sensitive group were significantly longer than those of control group,and half year survival rate and 1-year sur-vival rate were higher than control group,with statistical significance(P<0.05). The incidence of ADR was 82.61% in drug sensi-tive group and 80.43% in control group,without statistical significance(P>0.05). CONCLUSIONS:According to ATP-TCA test results,chemotherapy efficacy and survival situation of patients with platinum resistant recurrent ovarian cancer receiving targeted chemotherapy regimen are better than those receiving clinical empirical medication,and the incidence of ADR will not be influ-enced.
